Furthermore, the significantly enhanced efficacy of anti-PD-1 therapy in Myeloid-GAS6 KO mice underscores the promising potential of combining GAS6–TYRO3 axis inhibition with immune checkpoint blockade, especially in TEAD3-high acral melanoma—a subtype often associated with innate immunotherapy resistance and poorer clinical outcomes [39–41]. This evidence concerns the gene PDCD1 and acral lentiginous melanoma.